Trigen's innovative platelet adhesion inhibitor, PR-15, successfully completes first-in-man Phase I study

Data to be presented at the XXI Congress of the International Society of Thrombosis and Haemostasis

MUNICH, Germany, and LONDON, UK | May 01, 2007 |
Trigen, the cardiovascular drug discovery and development company, today announced the successful completion of its first-in-man Phase I study of PR-15, the company’s innovative platelet adhesion inhibitor.

Dr Sophie Combe, VP Clinical Development at Trigen commented “Based on the promising results of this first-in-man study, investigation of PR-15 in patients is warranted to further evaluate its safety profile and potential efficacy in the management of arterial thrombosis. These results validate the interest expressed by a number of parties in the PR-15 programme and in GPVI as an attractive target for intervention.”

The action of PR-15 has been likened to that of a ‘vascular sticking plaster’ due to its ability to prevent firm platelet adhesion to sites of arterial wall damage including ruptured atherosclerotic plaques. Such adhesion is the first step in platelet activation and aggregation leading to myocardial infarction (heart attack) and stroke and potentially stimulating further progression of atherosclerosis. PR-15 is being developed as a novel agent to treat acute arterial thrombosis and prevent or retard progression of atherosclerosis.

Dr Sanjay Kakkar, CEO at Trigen added, “These results are encouraging and confirm our belief that this innovative candidate drug may offer significant benefit to patients and prescribers. PR 15 is a potentially superior alternative to current acute anti-platelet agents as well as offering an important new option in the fight against restenosis and atherosclerosis.”

SOURCE: Trigen

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up